Hamps Bio IPO Day 2: Check subscriptions, key dates, GMP, price band and other details

The SME IPO of Hamps Bio was fully subscribed on Friday with an overall subscription of 23.92 times by 10:17 AM on the second day of bidding. The company aims to raise Rs 6.2 crore through the SME IPO with the shares set to list on the BSE SME platform. The issue will close on December 17.

Subscriptions from retail investors stood at 39.99 times ,while the non institutions investors had subscribed by 7.82 times on the first day of bidding.

Hamps Bio IPO: GMP

Ahead of the issue, Hamps Bio's unlisted shares were trading at Rs 91 per share on Monday in the unofficial market, reflecting a grey market premium (GMP) of 78.4% against the upper end of the IPO price band of Rs 51.

Hamps Bio IPO Size

The IPO is completely a fresh equity sale of 12.2 lakh shares and through the issue the company plans to raise around Rs 6.22 crore.

Hamps Bio IPO: Price Band

The company is offering its shares at Rs 51 per share, and investors can bid for 2000 shares in 1 lot.

Hamps Bio IPO: Issue Structure

About 50% of the offer is reserved for QIB investors, 35% for retail investors and the other 15% for non-institutional investors.

Hamps Bio IPO: Opening, Allotment and Listing Date

The IPO opened on December 13 and will close on December 17. The final allotment will likely be made on December 18. The company’s shares are scheduled to get listed on the BSE SME platform on December 20.

Hamps Bio IPO: Net Proceeds

The company said the net proceeds from the public offer will be used for purchase of plant and machinery for FMCG division, enhancing the visibility and awareness of the brand and general corporate purposes.

About Hamps Bio

The company is engaged in the ethical marketing and distribution of pharmaceutical formulation products across a wide range of dosages including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products.

Hamps Bio IPO: Industry Overview

India plays an important role in the global pharmaceuticals and vaccine industry. It is the largest provider of generic medicines globally. The country has a share of 20% in the global supply volume and contributes to around 60% of the global vaccines

Hamps Bio IPO: Financial Performance

For the period ended October 2024, the company clocked total revenues of Rs 4.36 crore and net profit of Rs 34 lakh.

Hamps Bio IPO: Lead Managers and Registrar

Marwadi Chandarana Intermediaries is acting as the lead manager to the issue and Bigshare Services is the registrar.

Also read | Purple United Sales IPO: Check allotment status, GMP and listing date

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)